Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis
A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are likely to have a higher risk of cardiovascular events. Incorporating fibrosis measurements into routine clinical care for rheumatoid arthritis patients could identify individuals with highest risk and enable risk management strategies.
Read more here or reach out to our experts if you have any questions.
Related
Julius Clinical Expands CNS and Cardiometabolic Capabilities with Post-Merger Growth and New Operations in Spain and Germany
Zeist, The Netherlands – [Date] – Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic indications, today announced continued growth in bookings in these key therap...
Cardiovascular risk in elderly with obesity and liver fibrosis: Benefits of statins
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
Insights from the CLEAR trial outcomes on MASLD and heart health
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...
